Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monopar Therapeutics Inc (MNPR) has shared an announcement.
Monopar Therapeutics Inc. has made significant progress in its MNPR-101 radiopharmaceutical program, leading to the filing of a provisional patent application to protect these recent advancements. This development could signal promising future prospects for the company and its stakeholders in the field of medical radiotherapeutics.
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.